• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators.一种基于动力学荧光的Ca2+动员检测方法,用于鉴定G蛋白偶联受体激动剂、拮抗剂和变构调节剂。
J Vis Exp. 2018 Feb 20(132):56780. doi: 10.3791/56780.
2
A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4.一种基于流式细胞术的检测方法,用于鉴定破坏荧光标记的CXC趋化因子配体12与CXC趋化因子受体4结合的化合物。
J Vis Exp. 2018 Mar 10(133):57271. doi: 10.3791/57271.
3
"Selective" Class C G Protein-Coupled Receptor Modulators Are Neutral or Biased mGlu Allosteric Ligands.“选择性”C 类 G 蛋白偶联受体调节剂是 mGlu 变构配体的中性或偏性配体。
Mol Pharmacol. 2018 May;93(5):504-514. doi: 10.1124/mol.117.111518. Epub 2018 Mar 7.
4
[G-protein-coupled receptors targeting: the allosteric approach].[靶向G蛋白偶联受体:变构方法]
Med Sci (Paris). 2012 Oct;28(10):845-51. doi: 10.1051/medsci/20122810012. Epub 2012 Oct 12.
5
Allosteric modulation of G-protein coupled receptors.G蛋白偶联受体的变构调节
Eur J Pharm Sci. 2004 Mar;21(4):407-20. doi: 10.1016/j.ejps.2003.11.007.
6
Allosteric modulators of rhodopsin-like G protein-coupled receptors: opportunities in drug development.视紫红质样 G 蛋白偶联受体的变构调节剂:药物开发的机遇。
Pharmacol Ther. 2012 Sep;135(3):292-315. doi: 10.1016/j.pharmthera.2012.06.002. Epub 2012 Jun 19.
7
Strategies for the identification of allosteric modulators of G-protein-coupled receptors.G 蛋白偶联受体变构调节剂的鉴定策略。
Biochem Pharmacol. 2011 Mar 15;81(6):691-702. doi: 10.1016/j.bcp.2010.12.012. Epub 2010 Dec 22.
8
Allosteric modulators of G-protein-coupled receptors.G蛋白偶联受体的变构调节剂
Curr Opin Pharmacol. 2003 Oct;3(5):551-6. doi: 10.1016/s1471-4892(03)00107-3.
9
Computational Advances for the Development of Allosteric Modulators and Bitopic Ligands in G Protein-Coupled Receptors.G蛋白偶联受体变构调节剂和双位点配体开发中的计算进展
AAPS J. 2015 Sep;17(5):1080-95. doi: 10.1208/s12248-015-9776-y. Epub 2015 May 5.
10
Allosteric Modulators of the Class A G Protein Coupled Receptors.A类G蛋白偶联受体的变构调节剂
Adv Exp Med Biol. 2016;917:185-207. doi: 10.1007/978-3-319-32805-8_9.

引用本文的文献

1
-IV restriction: a new configuration for metal bis-cyclam complexes as potent CXCR4 inhibitors.- IV 类限制:作为有效的 CXCR4 抑制剂的金属双环笼配合物的新构型。
Dalton Trans. 2024 Mar 19;53(12):5616-5623. doi: 10.1039/d3dt01729j.
2
Stimulation of the atypical chemokine receptor 3 (ACKR3) by a small-molecule agonist attenuates fibrosis in a preclinical liver but not lung injury model.小分子激动剂刺激非典型趋化因子受体 3(ACKR3)可减轻临床前肝脏而非肺部损伤模型中的纤维化。
Cell Mol Life Sci. 2022 May 13;79(6):293. doi: 10.1007/s00018-022-04317-y.
3
A Set of Experimentally Validated Decoys for the Human CC Chemokine Receptor 7 (CCR7) Obtained by Virtual Screening.通过虚拟筛选获得的一组经实验验证的人CC趋化因子受体7(CCR7)诱饵
Front Pharmacol. 2022 Mar 18;13:855653. doi: 10.3389/fphar.2022.855653. eCollection 2022.
4
Synthesis and Anti-HIV Activity of a Novel Series of Isoquinoline-Based CXCR4 Antagonists.新型异喹啉基CXCR4拮抗剂系列的合成及其抗HIV活性
Molecules. 2021 Oct 18;26(20):6297. doi: 10.3390/molecules26206297.

本文引用的文献

1
Harnessing CXCR4 antagonists in stem cell mobilization, HIV infection, ischemic diseases, and oncology.利用 CXCR4 拮抗剂进行干细胞动员、HIV 感染、缺血性疾病和肿瘤学研究。
Med Res Rev. 2018 Jul;38(4):1188-1234. doi: 10.1002/med.21464. Epub 2017 Aug 2.
2
Comparison of cell-based assays for the identification and evaluation of competitive CXCR4 inhibitors.用于鉴定和评估竞争性CXCR4抑制剂的细胞检测方法的比较
PLoS One. 2017 Apr 14;12(4):e0176057. doi: 10.1371/journal.pone.0176057. eCollection 2017.
3
The β-Arrestins: Multifunctional Regulators of G Protein-coupled Receptors.β-抑制蛋白:G蛋白偶联受体的多功能调节剂
J Biol Chem. 2016 Apr 22;291(17):8969-77. doi: 10.1074/jbc.R115.713313. Epub 2016 Mar 16.
4
Discovery of non-peptide small molecular CXCR4 antagonists as anti-HIV agents: Recent advances and future opportunities.发现非肽小分子 CXCR4 拮抗剂作为抗 HIV 药物:最新进展和未来机遇。
Eur J Med Chem. 2016 May 23;114:65-78. doi: 10.1016/j.ejmech.2016.02.051. Epub 2016 Feb 24.
5
CXCR4 over-expression and survival in cancer: a system review and meta-analysis.CXCR4过表达与癌症患者生存情况:一项系统评价与Meta分析
Oncotarget. 2015 Mar 10;6(7):5022-40. doi: 10.18632/oncotarget.3217.
6
The intricate role of CXCR4 in cancer.CXCR4在癌症中的复杂作用。
Adv Cancer Res. 2014;124:31-82. doi: 10.1016/B978-0-12-411638-2.00002-1.
7
Emerging paradigms in GPCR allostery: implications for drug discovery.G 蛋白偶联受体变构作用的新兴范式:对药物发现的影响。
Nat Rev Drug Discov. 2013 Aug;12(8):630-44. doi: 10.1038/nrd4052.
8
Discovery of positive allosteric modulators and silent allosteric modulators of the μ-opioid receptor.μ 阿片受体的正变构调节剂和沉默变构调节剂的发现。
Proc Natl Acad Sci U S A. 2013 Jun 25;110(26):10830-5. doi: 10.1073/pnas.1300393110. Epub 2013 Jun 10.
9
Positive allosteric modulators to peptide GPCRs: a promising class of drugs.正变构调节剂肽 GPCR :一类有前途的药物。
Acta Pharmacol Sin. 2013 Jul;34(7):880-5. doi: 10.1038/aps.2013.20. Epub 2013 Apr 29.
10
Small molecule inhibitors of CXCR4.CXCR4 的小分子抑制剂。
Theranostics. 2013;3(1):47-75. doi: 10.7150/thno.5376. Epub 2013 Jan 15.

一种基于动力学荧光的Ca2+动员检测方法,用于鉴定G蛋白偶联受体激动剂、拮抗剂和变构调节剂。

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators.

作者信息

Claes Sandra, D'huys Thomas, Van Hout Anneleen, Schols Dominique, Van Loy Tom

机构信息

Laboratory of Virology and Chemotherapy, Department of Microbiology and Immunology, Rega Institute for Medical Research, KU Leuven.

Laboratory of Virology and Chemotherapy, Department of Microbiology and Immunology, Rega Institute for Medical Research, KU Leuven;

出版信息

J Vis Exp. 2018 Feb 20(132):56780. doi: 10.3791/56780.

DOI:10.3791/56780
PMID:29553532
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5931321/
Abstract

G protein-coupled receptors (GPCRs) are of great importance to the pharmaceutical industry as they are involved in many human diseases and include well-validated targets for therapeutic intervention. Discovery of lead compounds, including small synthetic molecules, that specifically inhibit the receptor's function, is an important initial step in drug development and relies on sensitive, specific, and robust cell-based assays. Here, we describe a kinetic cellular assay with a fluorescent readout primarily designed to identify receptor-specific antagonists that inhibit the intracellular Ca release evoked upon the activation of the CXC chemokine receptor 4 (CXCR4) by its endogenous ligand, the CXC chemokine ligand 12 (CXCL12). A key advantage of this method is that it also enables screening of compounds endowed with intrinsic agonistic properties (i.e., compounds eliciting an increase in intracellular Ca concentration in the absence of CXCL12) or compounds modulating the receptor's function via interaction with allosteric binding sites (i.e., positive and negative allosteric modulators (PAMs and NAMs, respectively)). On the down side, autofluorescent compounds might interfere with the assay's readout, thereby hampering reliable data interpretation. Most likely this assay can be implemented, with minimal adaptations, as a generic drug discovery assay for many other GPCRs of which the activation leads to a release of intracellular Ca.

摘要

G蛋白偶联受体(GPCRs)对制药行业至关重要,因为它们与许多人类疾病相关,且是经过充分验证的治疗干预靶点。发现能够特异性抑制受体功能的先导化合物,包括小型合成分子,是药物开发的重要初始步骤,这依赖于灵敏、特异且可靠的基于细胞的检测方法。在此,我们描述了一种具有荧光读数的动力学细胞检测方法,其主要设计目的是识别受体特异性拮抗剂,这些拮抗剂可抑制内源性配体CXC趋化因子配体12(CXCL12)激活CXC趋化因子受体4(CXCR4)后引发的细胞内钙释放。该方法的一个关键优势在于,它还能够筛选具有内在激动特性的化合物(即在没有CXCL12的情况下能引起细胞内钙浓度升高的化合物)或通过与变构结合位点相互作用来调节受体功能的化合物(即分别为正变构调节剂和负变构调节剂(PAMs和NAMs))。不利的一面是,自发荧光化合物可能会干扰检测读数,从而妨碍可靠的数据解读。很可能只需进行最小程度的调整,该检测方法就能作为一种通用的药物发现检测方法用于许多其他激活后会导致细胞内钙释放的GPCRs。